Signaturefd LLC Boosts Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Signaturefd LLC grew its holdings in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) by 77.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 487 shares of the company’s stock after acquiring an additional 212 shares during the quarter. Signaturefd LLC’s holdings in Karuna Therapeutics were worth $154,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Karuna Therapeutics by 349.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,363 shares of the company’s stock worth $1,381,000 after acquiring an additional 3,392 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Karuna Therapeutics by 598.2% during the third quarter. SG Americas Securities LLC now owns 6,745 shares of the company’s stock worth $1,141,000 after acquiring an additional 5,779 shares in the last quarter. Hsbc Holdings PLC purchased a new position in shares of Karuna Therapeutics during the third quarter worth approximately $2,029,000. New York Life Investment Management LLC raised its stake in shares of Karuna Therapeutics by 140.1% during the third quarter. New York Life Investment Management LLC now owns 3,788 shares of the company’s stock worth $641,000 after acquiring an additional 2,210 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Karuna Therapeutics by 16.4% in the third quarter. Deutsche Bank AG now owns 51,584 shares of the company’s stock worth $8,722,000 after buying an additional 7,282 shares during the period.

Insider Activity

In other news, insider Stephen K. Brannan sold 5,000 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $316.13, for a total transaction of $1,580,650.00. Following the sale, the insider now owns 41,150 shares in the company, valued at approximately $13,008,749.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 13.20% of the company’s stock.

Analyst Upgrades and Downgrades

KRTX has been the topic of several analyst reports. Mizuho reaffirmed a “neutral” rating and issued a $330.00 target price (up from $245.00) on shares of Karuna Therapeutics in a research note on Friday, January 26th. HC Wainwright reaffirmed a “neutral” rating and issued a $330.00 target price on shares of Karuna Therapeutics in a research note on Thursday, March 14th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $330.00 target price on shares of Karuna Therapeutics in a research note on Tuesday, February 20th. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Karuna Therapeutics has a consensus rating of “Hold” and an average target price of $293.92.

Karuna Therapeutics Trading Up 0.0 %

Shares of Karuna Therapeutics stock opened at $329.83 on Monday. The company’s fifty day simple moving average is $325.66 and its two-hundred day simple moving average is $272.73. The company has a market cap of $12.58 billion, a P/E ratio of -28.14 and a beta of 1.18. Karuna Therapeutics, Inc. has a 12-month low of $158.38 and a 12-month high of $329.99.

Karuna Therapeutics (NASDAQ:KRTX) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($3.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.65) by ($0.36). The firm’s revenue was down 100.0% on a year-over-year basis. During the same quarter last year, the firm earned ($2.22) EPS. Analysts predict that Karuna Therapeutics, Inc. will post -11.96 EPS for the current fiscal year.

Karuna Therapeutics Company Profile

Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease.